Notably, epigenetic silencing of GPER as an anti-cancer mechanism is at odds with data in public repositories, showing that GPER is widely expressed, and rarely mutated, in solid or hematopoietic cancers and in cancer cell lines. The gene discussed is GPER1; the disease is hematopoietic and lymphoid cell neoplasm.